MMED MiniMed Group, Inc.
MiniMed Group (MMED) news
MiniMed Group, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MMED, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest MiniMed Group news
We have not published a story on MiniMed Group yet. When there is news, it will appear here.
What MiniMed Group does
MiniMed Group, Inc. is a medical technology company that develops, manufactures and markets solutions for the management of diabetes. Its platform for people with insulin therapy includes Automated Insulin Delivery (AID) systems that combine an insulin pump, infusion sets and reservoirs, a CGM sensor and a Smart Dosing algorithm. Its second-generation AID system is the MiniMed 780G, and it also sells the older MiniMed 770G, 740G, 720G and 630G systems. Its Smart Multiple Daily Injection system, the MiniMed Go system, includes the InPen smart insulin pen, a CGM sensor, and wraparound applications and services. The company says it is the first to commercialize all the constituent parts of these solutions. In the United States it distributes most products through the DME channel and a small percentage through the pharmacy channel. The company estimates its market at over $19 billion and expects it to grow at a compound annual growth rate above 10% from 2026 through at least 2030. Its primary medical specialists are endocrinologists, diabetologists, nurse practitioners, physician assistants and PCPs, and the filing cites real-world evidence and a randomized controlled study showing a 1.4% absolute improvement in A1C for the MiniMed 780G compared with standard of care.
| Product or program | What it is | Stage |
|---|---|---|
| MiniMed 780G AID system | Automated insulin delivery system with a Smart Dosing algorithm | |
| MiniMed Go (Smart MDI) system | Smart multiple daily injection system with InPen smart insulin pen and CGM | |
| MiniMed 770G, 740G, 720G and 630G systems | Older automated insulin delivery systems |
MiniMed Group annual financials
| Line | FY ended Apr 24, 2026 | FY ended Apr 25, 2025 |
|---|---|---|
| Revenue | $3.10 billion | $2.71 billion |
| Research and development | $448.0 million | $436.0 million |
| Net income (loss) | -$333.0 million | -$213.0 million |
| Cash from operations | -$197.0 million | $140.0 million |
| Cash and equivalents | $298.0 million | $11.0 million |
Questions about MiniMed Group
What is the ticker symbol of MiniMed Group?
MiniMed Group, Inc. trades under the ticker MMED on NASDAQ.
Where is MiniMed Group listed?
MiniMed Group, Inc. is listed on NASDAQ.
Which country or territory is MiniMed Group listed under?
Our directory records MiniMed Group, Inc. under United States.
Does aibio.space cover MiniMed Group?
aibio.space lists MiniMed Group, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What does MiniMed Group develop?
MiniMed Group, Inc. is a medical technology company that develops, manufactures and markets solutions for the management of diabetes. Its platform for people with insulin therapy includes Automated Insulin Delivery (AID) systems that combine an insulin pump, infusion sets and reservoirs, a CGM sensor and a Smart Dosing algorithm.
What is MiniMed 780G AID system from MiniMed Group?
MiniMed 780G AID system: Automated insulin delivery system with a Smart Dosing algorithm
What is MiniMed Go (Smart MDI) system from MiniMed Group?
MiniMed Go (Smart MDI) system: Smart multiple daily injection system with InPen smart insulin pen and CGM
What was MiniMed Group's revenue last year?
$3.10 billion for the fiscal year ended Apr 24, 2026, as reported to the SEC.
Is MiniMed Group profitable?
MiniMed Group, Inc. reported a net loss of $333.0 million for the fiscal year ended Apr 24, 2026, and used $197.0 million of cash in operations, per its annual report to the SEC.
How much does MiniMed Group spend on research and development?
$448.0 million in the fiscal year ended Apr 24, 2026, per its annual report.
How much cash does MiniMed Group have?
$207.0 million in cash at Jul 31, 2026, per its 10-Q.
Investor discussion: MiniMed Group
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Filed documents for a merger or acquisition. SEC Form S-4. Source
Stock chart
Listing details
- Company
- MiniMed Group, Inc.
- Ticker
- MMED
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio